PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice

Biological Chemistry

Volumn 392, Issue 3, 2011, Pages 233-237

  Reinhold, Dirk ^a   Bank, Ute ^b   Entz, Dominik ^a   Goihl, Alexander ^a   Stoye, Diana ^a   Wrenger, Sabine ^a   Brocke, Stefan ^c   Thielitz, Anja ^a   Stefin, Sofia ^b   Nordhoff, Karsten ^b   Heimburg, Anke ^b   Täger, Michael ^b   Ansorge, Siegfried ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b IMTM GmbH   (Germany)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; Multiple sclerosis; Peptidase inhibitors; PETIR ; T cell activation

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; MICROSOMAL AMINOPEPTIDASE; PETIR; PETIR 001; UNCLASSIFIED DRUG; DNA; PROTEINASE INHIBITOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOREGULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; ANIMAL; BIOSYNTHESIS; CELL LINE; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE STRAIN;

ANIMALIA; MUS;

ANIMALS; ANTIGENS, CD13; CELL LINE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DNA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; PROTEASE INHIBITORS; T-LYMPHOCYTES;

EID: 79953302035     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2011.024     Document Type: Article

References (30)

1. Ansorge, S., Bank, U., Heimburg, A., Helmuth, M., Koch, G., Tadje, J., Lendeckel, U., Wolke, C., Neubert, K., Faust, J., et al. (2009).Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions.Clin. Chem. Lab. Med. 47, 253-261.
2. Ansorge, S., Nordhoff, K., Bank, U., Heimburg, A., Julius, H., Breyer, D., Thielitz, A., Reinhold, D., and Täger, M. (2011).Novel aspects of cellular action of dipeptidyl peptidase IV/ CD26. Biol. Chem. 392, xxx-xxx.
3. Bank, U., Heimburg, A., Helmuth, M., Stefin, S., Lendeckel, U., Reinhold, D., Faust, J., Fuchs, P., Sens, B., Neubert, K., et al. (2006). Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) - a novel approach for the treatment of inflammatory bowel disease. Int. Immunopharmacol. 6, 1925-1934. (Pubitemid 44855708)
4. Bank, U., Tadje, J., Täger, M., Wolke, C., Bukowska, A., Ittenson, A., Reinhold, D., Helmuth, M., Ansorge, S., Shakespare, A., et al. (2007). Inhibition of alanyl-aminopeptidase on CD4qCD25q regulatory T-cells enhances expression of FoxP3 and TGF-b1 and ameliorates acute colitis in mice. Int. J. Mol. Med. 20, 483-492.
5. De Meester, I., Korom, S., Van Damme, J., and Scharpe, S. (1999).CD26, let it cut or cut it down. Immunol. Today 20, 367-375. (Pubitemid 29356431)
6. Fleischer, B. (1994). CD26: A surface protease involved in T-cell activation. Immunol. Today 15, 180-184. (Pubitemid 24131666)
7. Fleming, K.K., Bovaird, J.A., Mosier, M.C., Emerson, M.R., LeVine, S.M., and Marquis, J.G. (2005). Statistical analysis of data from studies on experimental autoimmune encephalomyelitis.J. Neuroimmunol. 170, 71-84. (Pubitemid 41740908)
8. Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., and Hartung, H.P. (2006). Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2, 201-211.
9. Jung, F.J., Yang, L., De Meester, I., Augustyns, K., Cardell, M., Hillinger, S., Vogt, P., Lardinois, D., Scharpe, S., Weder, W., et al. (2006). CD26/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats. J. Heart Lung Transplant. 25, 1109-1116. (Pubitemid 44311522)
10. Kähne, T., Lendeckel, U., Wrenger, S., Neubert, K., Ansorge, S., and Reinhold, D. (1999). Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth. Int. J. Mol. Med. 4, 3-15.
11. Korom, S., De Meester, I., Stadlbauer, T.H., Chandraker, A., Schaub, M., Sayegh, M.H., Belyaev, A., Haemers, A., Scharpe, S., and Kupiec-Weglinski, J.W. (1997). Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 63, 1495-1500. (Pubitemid 27237457)
12. Lambeir, A.M., Durinx, C., Scharpe, S., and De Meester, I. (2003).Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294. (Pubitemid 36775376)
13. Lendeckel, U., Arndt, M., Frank, K., Wex, T., and Ansorge, S. (1999). Role of alanyl aminopeptidase in growth and function of human T cells. Int. J. Mol. Med. 4, 17-27.
14. Lopez-Diego, R.S. and Weiner, H.L. (2008). Novel therapeutic strategies for multiple sclerosis - multifaceted adversary. Nat. Rev.Drug Discov. 7, 909-925.
15. Noseworthy, J.H., Lucchinetti, C., Rodriguez, M., and Weinshenker, B.G. (2000). Multiple sclerosis. N. Engl. J. Med. 343, 938-952.
16. Ohnuma, K., Dang, N.H., and Morimoto, C. (2008). Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 29, 295-301.
17. Reinhold, D., Bank, U., Bühling, F., Lendeckel, U., Faust, J., Neubert, K., and Ansorge, S. (1997a). Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-b 1 in PWM-stimulated PBMC and T cells. Immunology 91, 354-360. (Pubitemid 27304270)
18. Reinhold, D., Bank, U., Bühling, F., Täger, M., Born, I., Faust, J., Neubert, K., and Ansorge, S. (1997b). Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-b 1 (TGF-b1) in stimulated mouse splenocytes and thymocytes. Immunol. Lett. 58, 29-35. (Pubitemid 27232383)
19. Reinhold, D., Hemmer, B., Gran, B., Born, I., Faust, J., Neubert, K., McFarland, H.F., Martin, R., and Ansorge, S. (1998). Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4qT cell clones. J. Neuroimmunol. 87, 203-209. (Pubitemid 28319863)
20. Reinhold, D., Kähne, T., Steinbrecher, A., Wrenger, S., Neubert, K., Ansorge, S., and Brocke, S. (2002). The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol. Chem. 383, 1133-1138. (Pubitemid 35215059)
21. Reinhold, D., Biton, A., Pieper, S., Lendeckel, U., Faust, J., Neubert, K., Bank, U., Täger, M., Ansorge, S., and Brocke, S. (2006).Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int. Immunopharmacol. 6, 1935-1942. (Pubitemid 44855698)
22. Reinhold, D., Biton, A., Goihl, A., Pieper, S., Lendeckel, U., Faust, J., Neubert, K., Bank, U., Täger, M., Ansorge, S., et al. (2007).Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann. N. Y. Acad.Sci. 1110, 402-409. (Pubitemid 350043029)
23. Reinhold, D., Bank, U., Täger, M., Ansorge, S., Wrenger, S., Thielitz, A., Lendeckel, U., Faust, J., Neubert, K., and Brocke, S. (2008). DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: Implications for experimental encephalomyelitis and multiple sclerosis. Front. Biosci. 13, 2356-2363. (Pubitemid 351589259)
24. Riemann, D., Kehlen, A., and Langner, J. (1999). CD13 - not just a marker in leukemia typing. Immunol. Today 20, 83-88. (Pubitemid 29136633)
25. Schön, E., Mansfeld, H.W., Demuth, H.U., Barth, A., and Ansorge, S. (1985). The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed. Biochim.Acta 44, K9-K15.
26. Sedo, A. and Malik, R. (2001). Dipeptidyl peptidase IV-like molecules: Homologous proteins or homologous activities? Biochim.Biophys. Acta 1550, 107-116. (Pubitemid 34037997)
27. Steinbrecher, A., Reinhold, D., Quigley, L., Gado, A., Tresser, N., Izikson, L., Born, I., Faust, J., Neubert, K., Martin, R., et al. (2001). Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-b1 secretion in vivo. J. Immunol. 166, 2041-2048. (Pubitemid 32114693)
28. Tanaka, S., Murakami, T., Horikawa, H., Sugiura, M., Kawashima, K., and Sugita, T. (1997). Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19, 15-24. (Pubitemid 27259665)
29. Tanaka, S., Murakami, T., Nonaka, N., Ohnuki, T., Yamada, M., and Sugita, T. (1998). Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology 40, 21-26. (Pubitemid 28434950)
30. Yazbeck, R., Howarth, G.S., and Abbott, C.A. (2009). Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol. Sci. 30, 600-607.